CG Oncology Quarterly Income Statement
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CG Oncology revenue and earnings
In the quarter ended Jun 30, 2026, CG Oncology generated $1.2 million in revenue, up 0.0% from the same quarter a year earlier. CG Oncology reported a net loss of $79.1 million, compared with a loss of $41.4 million a year earlier. Operating margin was -7467.7%.
Diluted earnings per share came in at -$0.90.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16M | 1.08M | 2.32M | 1.67M | 0 | 52.00K | 456.00K | 43.00K | 111.00K | 529.00K | 1.00K | 9.00K |
| Revenue growth (YoY) | — | +1982.69% | +409.21% | +3774.42% | -100.00% | -90.17% | +45500.00% | +377.78% | — | +172.68% | — | — |
| Operating Expenses | — | — | — | — | 48.74M | 42.26M | 38.51M | 28.34M | 25.96M | 23.00M | 19.36M | 14.05M |
| Research & Development | 54.66M | 43.73M | 29.96M | 27.88M | 31.33M | 27.47M | 26.80M | 19.62M | 18.47M | 17.21M | 16.34M | 11.73M |
| Operating Income | -86.40M | -66.39M | -48.70M | -51.13M | -48.74M | -42.20M | -38.05M | -28.30M | -25.85M | -22.47M | -19.36M | -14.04M |
| Other Income (Expense) | 7.34M | 6.19M | 7.39M | 7.32M | 7.32M | 7.75M | 6.25M | 7.89M | 6.95M | 5.54M | 2.80M | 2.27M |
| Net Income | -79.06M | -60.20M | -41.31M | -43.81M | -41.43M | -34.45M | -31.80M | -20.41M | -18.90M | -16.93M | -16.55M | -11.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.90 | -0.71 | -0.52 | -0.57 | -0.54 | -0.45 | -0.47 | -0.30 | -0.28 | -0.36 | -4.50 | -4.00 |
| EPS (Diluted) | -0.90 | -0.71 | -0.52 | -0.57 | -0.54 | -0.45 | -0.47 | -0.30 | -0.28 | -0.36 | -4.50 | -4.00 |
| Shares Outstanding (Basic) | 88.20M | 84.52M | — | 76.73M | 76.23M | 76.19M | — | 67.14M | 66.65M | 47.06M | — | 4.38M |
| Shares Outstanding (Diluted) | 88.20M | 84.52M | — | 76.73M | 76.23M | 76.19M | — | 67.14M | 66.65M | 47.06M | — | 4.38M |
| EBITDA | -85.55M | -65.55M | -47.85M | -50.71M | -48.59M | -42.18M | -38.05M | -28.27M | -25.85M | -22.46M | -19.35M | -14.04M |
| Operating Margin | -7467.68% | -6130.10% | -2097.33% | -3068.97% | — | -81161.54% | -8344.08% | -65802.33% | -23290.99% | -4247.45% | -1935500.00% | -156033.33% |
| Net Margin | -6832.84% | -5558.82% | -1779.03% | -2629.53% | — | -66253.85% | -6973.25% | -47453.49% | -17028.83% | -3201.13% | -1655500.00% | -130755.56% |
This table shows 12 quarterly periods of CG Oncology's income statement, from Q2 2026 back to Q3 2023, across 13 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CGON's reporting calendar. What is a income statement?